Latest Share Chat

VEC.L Share News (VEC)

VEC.L Information

There is currently no data for VEC

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Fri, 04th Dec 2020 13:05

Tissue Regenix Group PLC - Leeds-based regenerative medical devices - Intends to appoint Brian Phillips and Trevor Phillips as independent non-executive directors. Notes the two are not related. Meanwhile, Alan Miller and Randeep Grewal step down as non-executive directors, effective immediately. Brian Philips co-founded Ethos partners in 2018. Ethos helps individual investors build private equity portfolios. Prior to Ethos, he was chief investment officer at Greenhill Capital Partners Europe LLP. Trevor Phillips currently is chair of respiratory monitoring firm NEPeSMO. Previously he was executive chair of former AIM listing hVivo and chief operating officer of FTSE 250 drug delivery products firm Vectura Group PLC.

Current stock price: 0.46 pence

Year-to-date change: down 54%

By Tom Waite; thomaslwaite@alliancenews.com

More News

18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

19 Nov 2020 20:25